Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

November 24, 2023

Study Completion Date

November 24, 2023

Conditions
Cervical CancerCervix Cancer
Interventions
BIOLOGICAL

VB10.16

Vaccination

BIOLOGICAL

Atezolizumab

Intravenously infusion

Trial Locations (21)

1200

Cliniques Universitaires Saint-Luc, Brussels

Hopital de Libramont, Brussels

1330

Multiprofile Hospital for Active Treatment for Women's Health - Nadezhda Sofia, Sofia

1431

"University Multiprofile Hospital for Active Treatment Sv. Ivan Rilski", Sofia

1527

"Multiprofile Hospital for Active Treatment Serdika EOOD", Sofia

1797

University Multiprofile Hospital For Active Treatment Sofiamed, Sofia

5000

Chu Ucl Namur, Namur

9000

Universitair Ziekenhuis Gent (Uz Gent), Ghent

10034

University Hospital Kralovske Vinohrady, Prague

53203

Nemocnice Pardubickeho Kraje Pardubicka Nemocnice, Pardubice

65653

Masaryk Memorial Cancer Institute, Brno

180 81

Nemocnice Na Bulovce, Prague

Unknown

Universitatsklinikum Augsburg, Augsburg

University Clinic Carl Gustav Carus, Dresden

Universitatsklinikum Hamburg-Eppendorf, Hamburg

Medizinische Hochschule Hannover, Hanover

Medizinische Fakulat Mannheim Der Universitat Heidelberg, Heidelberg

Jagielońskie Centum Innowacji, Centrum Badań Klinicznych JCI, Krakow

Wielkopolskie Centrum Onkologii, Poznan

'Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Warsaw

0379

Oslo University Hospital, Oslo

Sponsors
All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Vaccibody AS

INDUSTRY

lead

Nykode Therapeutics ASA

INDUSTRY

NCT04405349 - Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | Biotech Hunter | Biotech Hunter